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and outcome of both surgical disciplines and the impact of numerous other fac-
tors. METHODS: Data were extracted from a major public health insurance claims 
database (~ 8 million clients) during a 3-year period (2010-2012). Patients aged 4-17 
years with appendectomy were included. Logistic regression analysis for risk of 
a surgical complication within the first 180-postoperative days was performed. 
Complications were defined by ICD and OPS codes. RESULTS: 8,110 patients were 
analyzed (PedSurg: n= 1,937; GenSurg: n= 6,173). Laparoscopic appendectomy was 
performed significantly more frequently by GenSurg compared to PedSurg (79% vs. 
61%). The complication rate during initial stay and the readmission rate for surgical 
complications were significantly higher in patients treated by PedSurg compared to 
those operated on by GenSurg (2.9% vs. 1.7% and 3.4% vs. 2.2% respectively, p< 0.01). 
Logistic regression analysis revealed no differences between the two surgical spe-
cialities for the risk of surgical complications during the initial hospital stay and 
no differences for the risk of readmission for a surgical complication in younger 
patients (4-11 years). In contrast, the risk of readmission for surgical complications 
in adolescents (12-17 years) was significantly higher if the patient was operated on 
by PedSurg (p< 0.01). The results showed that patients treated with laparoscopy had 
a significantly lower risk for developing surgical complications within the first 180 
postoperative days than patients who underwent an open surgery (OR: 0.73, p< 0.1). 
No differences were found for the variables geographical region and working day vs. 
weekendsurgery. CONCLUSIONS: With overall low complication and readmission 
rates after appendectomy this study revealed an excellent quality of care for appen-
dicitis in Germany. However, the increased risk of readmission for surgical compli-
cations in adolescent patients operated by PedSurg deserves future investigation.
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OBJECTIVES: A high prevalence of chronic kidney disease (CKD) in hepatitis C virus 
(HCV)-infected patients has been reported in Taiwan. By contrast, several studies 
in the United States (US) have not found an increased prevalence of CKD, suggest-
ing a possible geographic variation. We systematically reviewed the literature to 
determine the risk of developing of CKD in HCV-infected individuals. METHODS: 
MEDLINE and PUBMED were searched to identify observational studies that had 
reported an association between HCV and CKD or end-stage renal disease (ESRD) 
through 2014. Quantitative estimates (hazard ratio (HR) or odds ratio (OR)) and the 
95% confidence intervals (CI) were extracted from each study. Studies were system-
atically reviewed in accordance with PRISMA guidelines, and a random-effects meta-
analysis was performed. RESULTS: Eleven studies evaluating the risk of developing 
CKD/ESRD in HCV-infected individuals (n= 265714) compared to uninfected controls 
(n= 1674104) were identified- 7 cohort studies and 4 cross-sectional studies. The 
average years of follow-up ranged from 2.1 to 7.4 years. Five studies were from the 
US and 6 were from Taiwan. The pooled HR of CKD/ESRD in HCV+ individuals from 
the cohort studies was significant at 1.36 [95%CI:1.13-1.58] whereas the pooled OR 
from the cross-sectional studies was not- 1.16 [95%CI:0.92-1.40]. The overall pooled 
risk ratio from the 11 studies indicated that HCV+ individuals had a 30% greater 
risk of developing CKD/ESRD compared to uninfected individuals: risk ratio 1.29 
[95%CI:1.13-1.45]. Country-stratified analysis yielded a significantly increased risk 
between HCV and CKD in the Taiwanese subgroup (risk ratio= 1.24 [95%CI:1.05-1.48]) 
but not among the US subgroup (risk ratio= 1.23 [95%CI:0.92-1.54]). Egger regression 
revealed no evidence of publication bias. CONCLUSIONS: HCV infection is associ-
ated with a greater risk of developing CKD/ESRD compared to uninfected controls. 
This risk appears to be geographically linked with patients in Taiwan at higher risk 
for HCV related CKD/ESRD than those in the US.
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OBJECTIVES: To quantify liver transplant risk and mean total costs in treated versus 
untreated patients diagnosed with hepatitis C virus (HCV). METHODS: The sample 
included individuals with commercial or Medicare Advantage insurance, aged 19-89, 
with ≥ 1 HCV diagnosis or HCV treatment prescription claim between 1/1/2008 and 
6/30/2013, excluding those diagnosed with hepatitis B. Patients were observed during 
their full post-index enrollment following date of transplant or first HCV diagnosis or 
prescription. Cox proportional-hazard regression approximated adjusted relative risk 
(aRR) of transplant in treated versus untreated individuals, controlling for age, gender, 
geographic location, Deyo-Charlson Comorbidity Index, RxRisk-V Score, and pre-index 
medical and pharmacy costs. Results were also generated by treatment adherence 
level based on proportion of days covered (≥ 80%, 50-79%, < 50%). Mean total costs 
(plan- and patient-paid) were assessed over the observation period using generalized 
linear models with log link and gamma distribution. RESULTS: 93.7% (40,338/43,046) 
of the sample had no evidence of HCV treatment. Incidence of liver transplant was 
0.79% in untreated and 1.77% in treated individuals. There was no evidence that HCV 
treatment was associated with lower risk of transplant (aRR= 1.01, 95% confidence 
interval [CI] 0.80-1.50). Transplant risk in treated individuals did not vary by adherence 
(50-79% aRR= 0.86 [95% CI 0.19-2.72]; < 50% aRR= 1.73 [95% CI 0.73-4.38]; reference group 
≥ 80%). Transplant recipients incurred significantly higher mean total costs compared 
to those without transplant ($154,250 vs. $38,128, p< 0.0001). Among transplant recipi-
ents, costs were higher for treated versus untreated patients ($237,949 vs $141,616, 
p< 0.0001). CONCLUSIONS: Despite adjusting for covariates, there was no evidence 
that HCV treatment reduced risk of liver transplant, suggesting that treated patients 
may be sicker and have unmeasured confounders. However, within the treated group, 
there was no change in risk of transplant by level of adherence, underscoring the need 
for further evidence on liver transplant outcomes.
interval [CI], (-14.89 to -3.89 minutes) (P = 0.0008); intraoperative blood loss (WMD, 
-12.41 mL; 95% CI, -18.20 to -6.62 mL) (P < 0.0001); length of hospital stay (weighted 
mean difference [WMD], -1.23 days; 95% CI, (-1.68 to -0.78 days) (P < 0.00001); and 
recovery time of intestine function (weighted mean difference [WMD], -2.96 days; 
95% CI, (-5.20 to -0.72 days) (P = 0.01). There were also significant differences in intra-
operative complication rate (OR= 0.23, 95% CI (0.06,0.87), P= 0.03) and in postoperative 
complication rate (OR= 0.11, 95% CI (0.02,0.62), P= 0.01). CONCLUSIONS: This meta-
analysis clearly demonstrates that compared with electrocautery, ultrasonic scalpel 
can statistically significant reduce operation time, intraoperative blood loss, length 
of hospital stay, recovery time of intestine function, intraoperative complication rate 
and postoperative complication rate in LC in Chines population. It evidences that in 
China, ultrasonic scalpel offers a wide range of clinically relevant advantages and all 
of these advantages have clear economic impacts in laparoscopic cholecystectomy.
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OBJECTIVES: To describe current clinical characteristics and healthcare utiliza-
tion of CHC patients treated with newer DAA-based regimens using claims-linked 
lab data from a large US health plan. METHODS: The Optum Research Database 
(ORD) with medical and pharmacy claims-linked lab data for commercially-
insured patients and Medicare Advantage beneficiaries was used. Patients with 
CHC ≥ 18 years treated with simeprevir (SMV) and/or sofosbuvir (SOF) regimens 
after Nov2013 and with 6-months baseline health plan enrollment were followed 
from treatment initiation until Jun2014. ORD contained 123.1M cumulative lives 
as of Jun2014. RESULTS: 1,844 CHC patients were treated with SOF+RBV (33%) SOF 
+PEG+RBV (32%), SMV+SOF (29%) and SMV+SOF+RBV (6%) (n= 51 were treated with 
other regimens and excluded from analysis). Less than half of patients had a cir-
rhosis diagnosis (37%). 24% had claims-based evidence of end-stage liver disease. 
Over half (65%) were male; 68% white and 14% black; mean age was 57.5 years 
(SD= 9.5). One-third (33%) were Medicare beneficiaries; 67% were commercially 
insured. Mean treatment duration for completed regimens (n= 339) was 10.7 weeks; 
over half of regimens had treatment durations of > 11 to ≤ 15 weeks (57%). Among 
patients with genotype results available (n= 597), 1a (51%) was most common, fol-
lowed by 1b (18%) and 2 (17%). Approximately one-third of patients with liver func-
tion test results (n= 658) had baseline advanced liver fibrosis (29% with APRI > 1.5; 
33% with FIB-4 > 3.25). Significant variations in treatment regimen were seen across 
liver disease severity subgroups, including those with advanced liver fibrosis most 
often being treated with SMV+SOF and SOF+RBV. Healthcare resource utilization 
and cost per SVR will be examined when post-treatment outcomes data are avail-
able. CONCLUSIONS: The analysis provides current CHC treatment patterns in a 
large US payer database, evidence of potential variation in newer DAA treatment 
utilization by clinical characteristics, and suggests a significantly higher proportion 
of patients receiving SMV+SOF±RBV had advanced liver fibrosis.
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OBJECTIVES: Infliximab is associated with fewer Crohn’s disease (CD)-associated 
hospitalizations in randomized efficacy trials. Testing the effectiveness of inflixi-
mab using administrative data is challenging because many clinical predictors (i.e., 
degree of inflammation) are not available in coded data. We aimed to examine the 
effectiveness of infliximab on CD-related hospitalizations adjusting for confound-
ers using high-dimensional data mining. METHODS: A sample of CD cases was 
identified by at least two encounters for International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) code 555 from all active duty U.S. 
military personnel with service between 2001 and 2012. CD is an exclusion crite-
rion for enlistment resulting in an incident cohort. Outpatient Current Procedural 
Terminology (CPT) codes were used to identify early infliximab use (within 6 months 
of diagnosis). The outcome of interest was hospitalization after 6 months of diag-
nosis. We applied an algorithm to select confounding risk factors with a minimum 
prevalence of 0.04%. Univariable predictors with p< 0.05 were eligible for the final 
multivariable selection model (inclusion threshold p< 0.01). RESULTS: During a 
median of 2.04 years of follow-up, 10% of the 990 eligible patients used infliximab 
within 6 months of diagnosis, 30% were hospitalized within the first 6 months of 
diagnosis and 9% were hospitalized after 6 months. Early infliximab use was associ-
ated with an increased odds of hospitalization > 6 months (OR 0.76; 95% CI 0.26 – 
2.21) after adjustment for 64 model-selected factors including number of encounters 
(OR 0.98), abdominal pain (OR 5.39) and CT scan (OR 5.76). CONCLUSIONS: In this 
incident cohort of CD, early use of infliximab was not associated with a statistically 
significant decreased in hospitalizations, although the direction of effect was similar 
to trial results. These findings indicate that high dimensional data mining adjust-
ment is an option for modeling medication-outcome relationships.
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OBJECTIVES: In Germany children with appendicitis are treated by pediatric sur-
geons (PedSurg) as well as general surgeons (GenSurg). We analyzed the treatment 
